Search

Your search keyword '"Gardini, Andrea Casadei"' showing total 14 results
Start Over Author "Gardini, Andrea Casadei" Language undetermined
14 results on '"Gardini, Andrea Casadei"'

1. Recalibrating survival prediction among patients receiving trans‐arterial chemoembolization for hepatocellular carcinoma

Author

Cucchetti, Alessandro, Giannini, Edoardo G., Mosconi, Cristina, Plaz Torres, Maria Corina, Pieri, Giulia, Farinati, Fabio, Rapaccini, Gian Ludovico, Di Marco, Maria, Caturelli, Eugenio, Sacco, Rodolfo, Cabibbo, Giuseppe, Campani, Claudia, Mega, Andrea, Guarino, Maria, Gasbarrini, Antonio, Svegliati‐Baroni, Gianluca, Foschi, Francesco Giuseppe, Missale, Gabriele, Masotto, Alberto, Nardone, Gerardo, Raimondo, Giovanni, Vidili, Gianpaolo, Brunetto, Maurizia Rossana, Sansone, Vito, Zoli, Marco, Azzaroli, Francesco, Trevisani, Franco, Biselli, Maurizio, Caraceni, Paolo, Gramenzi, Annagiulia, Rampoldi, Davide, Reggidori, Nicola, Santi, Valentina, Stefanini, Benedetta, Granito, Alessandro, Muratori, Luca, Piscaglia, Fabio, Tovoli, Francesco, Magalotti, Donatella, Dajti, Elton, Marasco, Giovanni, Ravaioli, Federico, Cappelli, Alberta, Golfieri, Rita, Renzulli, Matteo, Pelizzaro, Filippo, Penzo, Barbara, Marina Cela, Ester, Facciorusso, Antonio, Cacciato, Valentina, Casagrande, Edoardo, de Matthaeis, Nicoletta, Allegrini, Gloria, Lauria, Valentina, Ghittoni, Giorgia, Pelecca, Giorgio, Chegai, Fabrizio, Coratella, Fabio, Ortenzi, Mariano, Dell'Isola, Serena, Biasini, Elisabetta, Olivani, Andrea, Inno, Alessandro, Marchetti, Fabiana, Celsa, Ciro, Grova, Mauro, Stornello, Caterina, Busacca, Anita, Cammà, Calogero, Maria Rizzo, Giacomo Emanuele, Franzè, Maria Stella, Saitta, Carlo, Sauchella, Assunta, Napoli, Lucia, Bevilacqua, Vittoria, Berardinelli, Dante, Borghi, Alberto, Gardini, Andrea Casadei, Conti, Fabio, Dall'Aglio, Anna Chiara, Ercolani, Giorgio, Marra, Fabio, Di Bonaventura, Chiara, Gitto, Stefano, Adotti, Valentina, Coccoli, Pietro, Malerba, Antonio, Capasso, Mario, Morisco, Filomena, Oliveri, Filippo, Romagnoli, Veronica, Cucchetti, Alessandro, Giannini, Edoardo G., Mosconi, Cristina, Plaz Torres, Maria Corina, Pieri, Giulia, Farinati, Fabio, Rapaccini, Gian Ludovico, Di Marco, Maria, Caturelli, Eugenio, Sacco, Rodolfo, Cabibbo, Giuseppe, Campani, Claudia, Mega, Andrea, Guarino, Maria, Gasbarrini, Antonio, Svegliati‐Baroni, Gianluca, Foschi, Francesco Giuseppe, Missale, Gabriele, Masotto, Alberto, Nardone, Gerardo, Raimondo, Giovanni, Vidili, Gianpaolo, Brunetto, Maurizia Rossana, Sansone, Vito, Zoli, Marco, Azzaroli, Francesco, Trevisani, Franco, Biselli, Maurizio, Caraceni, Paolo, Gramenzi, Annagiulia, Rampoldi, Davide, Reggidori, Nicola, Santi, Valentina, Stefanini, Benedetta, Granito, Alessandro, Muratori, Luca, Piscaglia, Fabio, Tovoli, Francesco, Magalotti, Donatella, Dajti, Elton, Marasco, Giovanni, Ravaioli, Federico, Cappelli, Alberta, Golfieri, Rita, Renzulli, Matteo, Pelizzaro, Filippo, Penzo, Barbara, Marina Cela, Ester, Facciorusso, Antonio, Cacciato, Valentina, Casagrande, Edoardo, de Matthaeis, Nicoletta, Allegrini, Gloria, Lauria, Valentina, Ghittoni, Giorgia, Pelecca, Giorgio, Chegai, Fabrizio, Coratella, Fabio, Ortenzi, Mariano, Dell'Isola, Serena, Biasini, Elisabetta, Olivani, Andrea, Inno, Alessandro, Marchetti, Fabiana, Celsa, Ciro, Grova, Mauro, Stornello, Caterina, Busacca, Anita, Cammà, Calogero, Maria Rizzo, Giacomo Emanuele, Franzè, Maria Stella, Saitta, Carlo, Sauchella, Assunta, Napoli, Lucia, Bevilacqua, Vittoria, Berardinelli, Dante, Borghi, Alberto, Gardini, Andrea Casadei, Conti, Fabio, Dall'Aglio, Anna Chiara, Ercolani, Giorgio, Marra, Fabio, Di Bonaventura, Chiara, Gitto, Stefano, Adotti, Valentina, Coccoli, Pietro, Malerba, Antonio, Capasso, Mario, Morisco, Filomena, Oliveri, Filippo, and Romagnoli, Veronica

Subjects
Liver Cancer, Pre-TACE-Predict model, medicine.medical_specialty, business.industry, Trans-arterial chemoembolization, Pharmaceutical Science, hepatocellular carcinoma, medicine.disease, Gastroenterology, Complementary and alternative medicine, Internal medicine, Hepatocellular carcinoma, medicine, Pharmacology (medical), Trans arterial chemoembolization, business
Abstract

Background & Aims The Pre-TACE-Predict model was devised to assess prognosis of patients treated with trans-arterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). However, before entering clinical practice, a model should demonstrate that it performs a useful role. Methods We performed an independent external validation of the Pre-TACE model in a cohort that differs in setting and time period from the one that generated the original model. Data from 826 patients treated with TACE for naïve HCC (2008-2018) were used to assess calibration and discrimination of the Pre-TACE-Predict model. Results The four risk-categories identified by the Pre-TACE-Predict model had gradient monotonicity, with median survivals of 52.0, 36.2, 29.9, and 14.1 months respectively. However, predicted survivals systematically underestimated observed survivals (R2: 0.667). A recalibration was adopted maintaining fixed the prognostic index and modifying the baseline survival function. This resulted in an almost perfect calibration (R2: 0.995) in all the four risk categories. Cox regressions showed that aetiology and macrovascular invasion, included in the Pre-TACE-Predict model, had no prognostic impact in the present study population, and that coefficients for tumour size and multiplicity were overestimated. The c-index was similar to that of the m-HAP-III, but higher than those of HAP, m-HAP-II and the six-and-twelve models. Conclusions The recalibration of Pre-TACE-Predict model improved the estimation of survival probabilities of HCC patients treated with TACE. The highest discriminatory ability of the Pre-TACE-model in comparison to other available models, together with risk stratification and recalibration, makes it the best prognostic tool currently available for these patients.

Published
2021
Full Text
View/download PDF

2. Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients

Author

Cucchetti, Alessandro, D’Amico, Gennaro, Trevisani, Franco, Morelli, Maria Cristina, Vitale, Alessandro, Pinna, Antonio Daniele, Cescon, Matteo, Cillo, Umberto, Burra, Patrizia, Russo, Francesco P., Mescoli, Claudia, Rendina, Maria, Lupo, Luigi G., Losito, Francesco, Fucilli, Fabio, Brancaccio, Giusep-Pina, Persico, Marcello, Viganò, Luca, Iavarone, Massimo, D’Ambrosio, Roberta, Sangiovanni, Angelo, Renzulli, Matteo, Galati, Giovanni, Ponziani, Francesca Romana, Pompili, Maurizio, Miele, Luca, Grieco, Antonio, Rapaccini, Gianlodovico, Gasbarrini, Antonio, Sandri, Giovanni Battisa Levi, Lai, Quirino, Melandro, Fabio, Rossi, Massimo, Lenci, Ilaria, Manzia, Tommaso Maria, Tortora, Raffaella, Di Costanzo, Giovan Giuseppe, Sacco, Rodolfo, Simonetti, Natalia, Morisco, Filomena, Guarino, Maria, Cabibbo, Giuseppe, Bhoori, Carlo Sposito Sherrie, Di Sandro, Stefano, Foschi, Francesco Giuseppe, Gardini, Andrea Casadei, Nicolini, Daniele, Mazzocato, Susanna, Alba, Kostandini, Violi, Paola, Baccarani, Umberto, Pravisani, Riccardo, A. Cucchetti, G. D'Amico, F. Trevisani, M.C. Morelli, A. Vitale, A.D.Pinna, M. Cescon, Cucchetti, Alessandro, D’Amico, Gennaro, Trevisani, Franco, Morelli, Maria Cristina, Vitale, Alessandro, Pinna, Antonio Daniele, Cescon, Matteo, Cillo, Umberto, Burra, Patrizia, Russo, Francesco P., Mescoli, Claudia, Rendina, Maria, Lupo, Luigi G., Losito, Francesco, Fucilli, Fabio, Brancaccio, Giusep-Pina, Persico, Marcello, Viganò, Luca, Iavarone, Massimo, D’Ambrosio, Roberta, Sangiovanni, Angelo, Renzulli, Matteo, Galati, Giovanni, Ponziani, Francesca Romana, Pompili, Maurizio, Miele, Luca, Grieco, Antonio, Rapaccini, Gianlodovico, Gasbarrini, Antonio, Sandri, Giovanni Battisa Levi, Lai, Quirino, Melandro, Fabio, Rossi, Massimo, Lenci, Ilaria, Manzia, Tommaso Maria, Tortora, Raffaella, Di Costanzo, Giovan Giuseppe, Sacco, Rodolfo, Simonetti, Natalia, Morisco, Filomena, Guarino, Maria, Cabibbo, Giuseppe, Bhoori, Carlo Sposito Sherrie, Di Sandro, Stefano, Foschi, Francesco Giuseppe, Gardini, Andrea Casadei, Nicolini, Daniele, Mazzocato, Susanna, Alba, Kostandini, Violi, Paola, Baccarani, Umberto, and Pravisani, Riccardo

Subjects
Male, Time Factors, Sustained Virologic Response, Hepatocellular carcinoma, Hepacivirus, Direct-acting antiviral, Direct-acting antivirals, medicine.disease_cause, Gastroenterology, Competing risk, Hepatitis C, Markov model, Survival benefit, Sustained virological response, Hepatology, 0302 clinical medicine, Risk Factors, 030212 general & internal medicine, biology, Incidence, Incidence (epidemiology), Liver Neoplasms, Middle Aged, Markov Chains, Competing risk Direct-acting antivirals Hepatitis C Hepatocellular carcinoma Markov model Survival benefit Sustained virological response, Italy, Liver Neoplasm, Female, 030211 gastroenterology & hepatology, Human, Adult, medicine.medical_specialty, Carcinoma, Hepatocellular, Time Factor, Hepatitis C virus, Antiviral Agents, 03 medical and health sciences, Internal medicine, medicine, Humans, Antiviral Agent, Hepaciviru, business.industry, Risk Factor, Carcinoma, Hepatocellular, Markov Chain, medicine.disease, biology.organism_classification, digestive system diseases, Settore MED/18 - Chirurgia Generale, Liver function, Varices, business
Abstract

Background: The achievement of high rates of sustained virological response (SVR) with direct-acting antivirals (DAAs) in hepatitis C virus (HCV) infected patients will reduce decompensating terminal events. Aims: To investigate whether hepatocellular carcinoma (HCC) occurrence could change due to the DAA-induced increase in life-expectancy. Methods: A Markov model was built on clinical data of 494 cirrhotic patients and available literature to estimate probabilities of “death before HCC” and of “HCC occurrence” without and with DAA. Results: In comparison to untreated patients, DAA therapy reduced the 20-year mortality before HCC by 21.9% in patients without varices and by 21.5% in those with varices, considering an SVR of 95% and no direct effect on hepatocarcinogenesis. Tumour occurrence increased by 5%–8.2% and the proportion of HCCs diagnosed in compensated stages increased to >98%. If we consider DAA as having “anti-tumoral” effects, the benefit becomes greater, achieving a 20-year survival of 81.5% in patients without varices, and 52.2% in patients with varices. Instead, if we consider DAA as having a “pro-tumoral” effect, then, the increased incidence of HCC nullifies the survival benefits. Conclusion: DAAs drastically reduce the mortality caused by the liver function worsening, increasing the proportion of HCCs diagnosed in compensated stages. Knowledge of the DAA effect on hepatocarcinogenesis remains pivotal. © 2017 Editrice Gastroenterologica Italiana S.r.l.

Published
2018
Full Text
View/download PDF

3. Retrospective Analysis on the Management of Metastatic Gastric Cancer Patients. A Mono-institutional Experience. What happens in Clinical Practice?

Author

Monti, Manlio, Foca, Flavia, Gardini, Andrea Casadei, Valgiusti, Martina, Frassineti, Giovanni Luca, Amadori, Dino, Monti, Manlio, Foca, Flavia, Gardini, Andrea Casadei, Valgiusti, Martina, Frassineti, Giovanni Luca, and Amadori, Dino

Subjects
Male, Cancer Research, Outcome research, Dose reduction, Second-line, Kaplan-Meier Estimate, Clinical practice, Drug Administration Schedule, 03 medical and health sciences, End of life, Metastatic gastric cancer, Medicine (all), 0302 clinical medicine, Recurrence, Stomach Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Humans, 030212 general & internal medicine, Aged, Neoplasm Staging, Retrospective Studies, Aged, 80 and over, Disease Management, General Medicine, Middle Aged, Treatment Outcome, Italy, Oncology, 030220 oncology & carcinogenesis, Female, Neoplasm Grading
Abstract

Aims and background Few studies show what happens outside of randomized clinical trials. The purpose of the study was to describe the clinical management of metastatic gastric cancer patients resident in the Forlì area from 2000 to 2009. Methods and study design A total of 270 metastatic gastric cancer patients at diagnosis or relapse were considered. Data from medical records were analysed, and survival probabilities were calculated using the Kaplan-Meier method. Results A total of 115 patients received best supportive care, 155 at least one line of chemotherapy, 71 (45.8%) underwent second-line therapy, and 49 (31.6%) required a drug dose reduction during the first cycle of first-line therapy. Twelve (7.7%) patients died within 15 days of finishing the last chemotherapy. Median overall survival with best supportive care or chemotherapy was 3 months (95% CI, 2–4) and 11 months (95% CI, 9–12) (P Conclusions Drug dose reductions and delivery of second-line therapy were common. Chemotherapy given towards the end of life was similar to other experiences. Median overall survival was similar to randomized clinical trials.

Published
2013
Full Text
View/download PDF

4. Additional file 2: of Prevalence of and risk factors for fatty liver in the general population of Northern Italy: the Bagnacavallo Study

Author

Foschi, Francesco, Bedogni, Giorgio, Domenicali, Marco, Giacomoni, Pierluigi, Dall’Aglio, Anna, Dazzani, Francesca, Lanzi, Arianna, Conti, Fabio, Savini, Sara, Saini, Gaia, Bernardi, Mauro, Andreone, Pietro, Gastaldelli, Amalia, Gardini, Andrea Casadei, Tiribelli, Claudio, Bellentani, Stefano, and Stefanini, Giuseppe

Subjects
health care economics and organizations
Abstract

Table S2. Comparison of the citizens with and without liver ultrasonography among those with normal liver enzymes. In this table we compared the 1810 citizens without altered liver enzymes (ALE-) and with liver ultrasonography (LUS) to the 1692 ALE- citizens without LUS. (DOCX 18â kb)

Published
2018
Full Text
View/download PDF

5. Additional file 1: of Prevalence of and risk factors for fatty liver in the general population of Northern Italy: the Bagnacavallo Study

Author

Foschi, Francesco, Bedogni, Giorgio, Domenicali, Marco, Giacomoni, Pierluigi, Dall’Aglio, Anna, Dazzani, Francesca, Lanzi, Arianna, Conti, Fabio, Savini, Sara, Saini, Gaia, Bernardi, Mauro, Andreone, Pietro, Gastaldelli, Amalia, Gardini, Andrea Casadei, Tiribelli, Claudio, Bellentani, Stefano, and Stefanini, Giuseppe

Subjects
health care economics and organizations
Abstract

Table S1. Comparison of the citizens with and without liver ultrasonography among those with altered liver enzymes. In this table we compared the 349 citizens with altered liver enzymes (ALE+) and with liver ultrasonography (LUS) to the 28 ALE+ citizens without LUS. (DOCX 18â kb)

Published
2018
Full Text
View/download PDF

9. endothelial nitric oxide synthase(eNOS) polymorphisms in relation to outcome in advanced HCC patients receiving sorafenib. Final results of ePHAS study

Author

Gardini, Andrea Casadei, Marisi, Giorgia, Faloppi, Luca, Scarpi, Emanuela, Scartozzi, Mario, Foschi, Francesco Giuseppe, Iavarone, Massimo, Lauletta, Gianfranco, Corbelli, Jody, Tenti, Elena, Facchetti, Floriana, Corte, Cristina Della, Tamberi, Stefano, Nanni, Oriana, Stefanu Cascinu, Amadori, Dino, Ulivi, Paola, and Frassineti, Giovanni Luca

Published
2015
Full Text
View/download PDF

10. The genomic landscape of IDH1 mutant intrahepatic cholangiocarcinoma: a multicentre comprehensive analysis

Author

Rimini, Margherita, Macarulla, Teresa Mercade, Burgio, Valentina, Lonardi, Sara, Niger, Monica, Scartozzi, Mario, Raposelli, Ilario, Aprile, Giuseppe, Ratti, Francesca, Pedica, Federica, Verdaguer, Helena, Nappo, Floriana, Nichetti, Federico, Lai, Eleonora, Valgiusti, Martina, Cappetta, Alessandro, Carles Fabregat Franco, Fassan, Matteo, Braud, Filippo, Puzzoni, Marco, Frassineti, Giovanni Luca, Simionato, Francesca, Cobelli, Francesco, Aldrighetti, Luca, Fornaro, Lorenzo, Cascinu, Stefano, and Gardini, Andrea Casadei

Subjects
Hepatology

12. Preoperative Chemotherapy and Resection Margin Status in Colorectal Liver Metastasis Patients: A Propensity Score-Matched Analysis

Author

Solaini, L., Gardini, A., Passardi, A., Mirarchi, M. T., D Acapito, F., La Barba, G., Cucchi, M., Gardini, A. C., Frassineti, G. L., Cucchetti, A., Giorgio Ercolani, Solaini, Leonardo, Gardini, Andrea, Passardi, Alessandro, Mirarchi, Maria Teresa, D'Acapito, Fabrizio, La Barba, Giuliano, Cucchi, Michele, Casadei Gardini, Andrea, Frassineti, Giovanni L, Cucchetti, Alessandro, Ercolani, Giorgio, and Gardini, Andrea Casadei

Subjects
Male, Liver Neoplasms, Margins of Excision, Antineoplastic Agents, Middle Aged, Neoadjuvant Therapy, Survival Rate, Treatment Outcome, Preoperative chemotherapy, propensity score, colorectal liver metastasis, hepatectomy, Chemotherapy, Adjuvant, Chemotherapy, Hepatectomy, Humans, Female, Aged, Colorectal Neoplasms, Propensity Score, Retrospective Studies, Adjuvant
Abstract

In this article, we compared the early and long-term outcomes of patients with metastatic colorectal cancer treated with chemotherapy followed by resection with those of patients undergoing surgery first, focusing our analysis on resection margin status. Patients who underwent liver resection with curative intent for colorectal liver metastases from July 2001 to January 2018 were included in the analysis. Propensity score matching was used to reduce treatment allocation bias. The cohort comprised 164 patients; 117 (71.3%) underwent liver resection first, whereas the remaining 47 (28.7%) had preoperative chemotherapy. After a 1:1 ratio of propensity score matching, 47 patients per group were evaluated. A positive resection margin was found in 13 patients in the surgery-first group (25.5%) versus 4 (8.5%) in the preoperative chemotherapy group (P = 0.029). Postmatched logistic regression analysis showed that only preoperative chemotherapy was significantly associated with the rate of positive resection margin (odds ratio 0.24, 95% confidence interval 0.07-0.81; P = 0.022). Median follow-up was 41 months (interquartile range 8-69). Cox proportional hazard regression analysis revealed that only positive resection margin was a significant negative prognostic factor (hazard ratio 2.2, 95% CI 1.18-4.11; P = 0.014). Within the preoperative chemotherapy group, median overall survival was 40 months in R0 patients and 10 months in R1 patients (P = 0.016). Although preoperative chemotherapy in colorectal liver metastasis patients may affect the rate of positive resection margin, its impact on survival seems to be limited. In the present study, the most important prognostic factor was the resection margin status.

Published
2019

13. Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients: indicators of suspected adverse reactions

Author

Silvia Menozzi, Dino Amadori, Giovanni Luca Frassineti, Erica Bianchini, Elena Tenti, Oriana Nanni, Martina Valgiusti, Silvia Restuccia, Antonio Maugeri, Simonetta Palazzini, Andrea Casadei Gardini, Carla Masini, Martina Minguzzi, Emanuela Scarpi, Maria Laura Gallani, Gardini, Andrea Casadei, Tenti, Elena, Masini, Carla, Nanni, Oriana, Scarpi, Emanuela, Valgiusti, Martina, Restuccia, Silvia, Gallani, Maria Laura, Palazzini, Simonetta, Bianchini, Erica, Menozzi, Silvia, Maugeri, Antonio, Amadori, Dino, Minguzzi, Martina, and Frassineti, Giovanni Luca

Subjects
0301 basic medicine, Niacinamide, medicine.medical_specialty, Organoplatinum Compounds, Antineoplastic Agents, Docetaxel, Capecitabine, Oxaliplatin, Pathology section, Pharmacovigilance, Sorafenib, Oncology, Drug Administration Schedule, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Neoplasms, Medicine, Humans, Medical prescription, Adverse effect, Retrospective Studies, business.industry, Phenylurea Compounds, capecitabine, oxaliplatin, Retrospective cohort study, Carboplatin, Surgery, 030104 developmental biology, Treatment Outcome, chemistry, 030220 oncology & carcinogenesis, Taxoids, Clinical Research Paper, business, medicine.drug
Abstract

Antiblastic drugs have a high number of potential side-effects. Paradoxically, according to the National Network of Pharmacovigilance, the number of reported adverse reactions to these agents is proportionally lower than that registered for non antiblastic drugs. Critical phenomena such as treatment interruptions and significant dose reductions within the first two months of use may be indicators of adverse drug reactions. The aim of the present study was to increase our knowledge of pharmacovigilance to facilitate the actions taken to improve the risk-benefit profile of cancer drugs and, consequently, their safety. This retrospective observational survey was carried out on prescriptions from 1st January 2012 to 31st December 2012. Dose reductions of more than 10% during the first 90 days of therapy were considered as a surrogate indicator of an adverse reaction. Dose interruptions during the first 60 days of therapy were taken into consideration. Of the12,472 patients 1,248 underwent a dose reduction. The drugs that most often required a dose reduction were paclitaxel and oxaliplatin (17.4% and 17.3%, respectively), docetaxel (14.8%), carboplatin (15%), fluorouracil (10.7%) and, among oral medications, capecitabine (6.9%). Of the 1896 patients treated with the same drugs, 9.7% interrupted treatment. Patients required a lower dose reduction than that reported by other authors. Around 15% of cases underwent a 30% dose reduction within three months of starting therapy, indicating a possible adverse reaction. Constant monitoring of dose prescription and continuous training of medical and nursing staff are clearly needed to increase awareness of the importance of reporting adverse events.

Published
2016

14. Pharmacological interaction and side effects in oncohaematology: a retrospective observational study

Author

Elena Tenti, Giovanni Marconi, Nicoletta Testoni, Claudia Venturi, Cristina Papayannidis, Antonella Padella, Sarah Parisi, Chiara Sartor, Emanuela Ottaviani, Francesco Emanuele Antonio Brera, Giovanni Martinelli, Stefania Paolini, Maria Chiara Fontana, Giorgia Simonetti, Viviana Guadagnuolo, Andrea Casadei Gardini, Carmen Baldazzi, Tenti, Elena, Gardini, Andrea Casadei, Papayannidis, Cristina, Marconi, Giovanni, Simonetti, Giorgia, Parisi, Sarah, Paolini, Stefania, Sartor, Chiara, Ottaviani, Emanuela, Venturi, Claudia, Fontana, MARIA CHIARA, Padella, Antonella, Guadagnuolo, Viviana, Testoni, Nicoletta, Baldazzi, Carmen, Brera, Francesco, and Martinelli, Giovanni

Subjects
Drug, Cancer Research, medicine.medical_specialty, business.industry, media_common.quotation_subject, fungi, food and beverages, Retrospective cohort study, Oncology, Pharmacokinetics, Internal medicine, Pharmacodynamics, medicine, sense organs, skin and connective tissue diseases, business, oncoematologia, farmacologia, media_common
Abstract

e18235Background: Patients affected by oncohaematology pathology follow multiple therapies that can contribute to the drug interactions resulting in change in pharmacokinetics or pharmacodynamics o...

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results